Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCP1904-3
- Development stage
- Phase 3
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HCP1904-3 is a small molecule drug candidate developed by Hanmi Pharmaceutical for the treatment of essential hypertension. It is part of the HCP1904 series, which has been evaluated in multiple phase 1 and phase 3 clinical trials for its efficacy and safety in patients with high blood pressure inadequately controlled on monotherapy. The specific mechanism of action, molecular targets, and active ingredients have not been publicly disclosed as of June 2025. The drug is administered orally and has not received regulatory approval from major agencies such as FDA, EMA, or others[2][3][1].
- Other names
- HCP1904-3HCP-1904-3HCP 1904-3
Beyond the preview
Go deeper on HCP1904-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCP1904-3.